Literature DB >> 8923591

Immunopathogenesis of systemic sclerosis.

B White1.   

Abstract

The information outlined above can be used to generate a model of the immunopathogenesis of SSc (Fig. 3). This model includes a susceptible host, with age greater than 25 and female gender being risk factors. The model also includes exposure to exogenous agents, which could be different in different individuals and may include inhaled or ingested chemicals or infectious agents. An early event is T-cell activation, with infiltration in the skin and internal organs. Activation of the T cells is a selective process that appears to be influenced by antigen in SSc patients. The importance of a particular T-cell subpopulation may depend upon the organ involved and the stage of the disease. CD4+ T cells predominate in the skin. In contrast, CD8+ T cells are increased in the lungs of patients with alveolitis, where they are oligoclonal, showing evidence of antigen-driven selection. V delta 1+ gamma/delta T cells are increased in both the blood and lungs of SSc patients and also show evidence of selection by antigen. B cells are activated early, with polyclonal activation leading to hypergammaglobulinemia. SSc-specific autoantibodies target DNA topoisomerase I, centromeric proteins, and RNA polymerases I and III. Characteristics of autoantibodies in SSc suggest that the target antigens are presented to the immune system as native molecules or even part of a multiunit complex. There is some homology between viruses and autoantibody targets in SSc, which suggests that molecular mimicry may play a role in initiating the antibody response. Many nonspecific inflammatory cells infiltrate the tissues and show evidence of activation. These include macrophages and monocytes, mast cells, eosinophils, basophils, and natural killer cells. Soluble mediators made by these T cells, B cells, and nonspecific inflammatory cells can activate and damage fibroblasts, endothelial cells, and other vascular cells. The relative importance of the various candidate cytokines, the temporal sequence of their production, and their cellular sources remain largely to be defined. There may be some contribution of direct T-cell cytotoxicity or antibody-dependent cellular cytoxicity to the tissue damage that occurs.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8923591     DOI: 10.1016/s0889-857x(05)70296-9

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  28 in total

1.  Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease.

Authors:  M Binks; J R Passweg; D Furst; P McSweeney; K Sullivan; C Besenthal; J Finke; H H Peter; J van Laar; F C Breedveld; W E Fibbe; D Farge; E Gluckman; F Locatelli; A Martini; F van den Hoogen; L van de Putte; A V Schattenberg; R Arnold; P A Bacon; P Emery; I Espigado; B Hertenstein; F Hiepe; A Kashyap; I Kötter; A Marmont; A Martinez; M J Pascual; A Gratwohl; H G Prentice; C Black; A Tyndall
Journal:  Ann Rheum Dis       Date:  2001-06       Impact factor: 19.103

2.  Increased CD8+ T cell apoptosis in scleroderma is associated with low levels of NF-kappa B.

Authors:  Aharon Kessel; Itzhak Rosner; Michael Rozenbaum; Devy Zisman; Anca Sagiv; Zehava Shmuel; Edmond Sabo; Elias Toubi
Journal:  J Clin Immunol       Date:  2004-01       Impact factor: 8.317

3.  Elevated serum TRAIL levels in scleroderma patients and its possible association with pulmonary involvement.

Authors:  Noha A Azab; Hanaa M Rady; Samar A Marzouk
Journal:  Clin Rheumatol       Date:  2012-06-23       Impact factor: 2.980

4.  Peripheral T lymphocytes from patients with early systemic sclerosis co-cultured with autologous fibroblasts undergo an oligoclonal expansion similar to that occurring in the skin.

Authors:  Raffaele De Palma; Francesco Del Galdo; Salvatore Lupoli; Paolo Altucci; Gianfranco Abbate; Gabriele Valentini
Journal:  Clin Exp Immunol       Date:  2006-04       Impact factor: 4.330

5.  A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease.

Authors:  Arnold E Postlethwaite; Weng Kee Wong; Philip Clements; Soumya Chatterjee; Barri J Fessler; Andrew H Kang; Joseph Korn; Maureen Mayes; Peter A Merkel; Jerry A Molitor; Larry Moreland; Naomi Rothfield; Robert W Simms; Edwin A Smith; Robert Spiera; Virginia Steen; Kenneth Warrington; Barbara White; Frederick Wigley; Daniel E Furst
Journal:  Arthritis Rheum       Date:  2008-06

Review 6.  Biomarkers in systemic sclerosis.

Authors:  Susan V Castro; Sergio A Jimenez
Journal:  Biomark Med       Date:  2010-02       Impact factor: 2.851

7.  Increased interferon-gamma (IFN-gamma) levels produced in vitro by alloactivated T lymphocytes in systemic sclerosis and Raynaud's phenomenon.

Authors:  M Molteni; S Della Bella; B Mascagni; S Bazzi; C Zulian; S Compasso; M Lessi; R Scorza
Journal:  Clin Exp Immunol       Date:  1999-04       Impact factor: 4.330

8.  Increased transendothelial migration of scleroderma lymphocytes.

Authors:  G H Stummvoll; M Aringer; J Grisar; C W Steiner; J S Smolen; R Knobler; W B Graninger
Journal:  Ann Rheum Dis       Date:  2004-05       Impact factor: 19.103

9.  Serum concentrations of soluble P-selectin glycoprotein ligand-1 are increased in patients with systemic sclerosis: association with lower frequency of pulmonary fibrosis.

Authors:  K Yanaba; K Takehara; S Sato
Journal:  Ann Rheum Dis       Date:  2004-05       Impact factor: 19.103

Review 10.  The immune pathogenesis of scleroderma: context is everything.

Authors:  Matthew B Greenblatt; Antonios O Aliprantis
Journal:  Curr Rheumatol Rep       Date:  2013-01       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.